About This Video
FIRMAGON® (degarelix for injection), a new injectable prostate cancer medication for the treatment of advanced prostate cancer, is now available in the U.S. The treatment rapidly inhibits the production of testosterone, a hormone that stimulates cancer growth. FIRMAGON was approved by the U.S. Food and Drug Administration (FDA) on December 24, 2008 and was granted marketing authorization by the European Commission on February 19, 2009. It was launched in the U.S. in March 2009 under the generic name, degarelix.
For more information, please visit http://www.firmagon.us
This website uses Adobe® Flash™ Player 9
Download Flash Now
If you are using Internet Explorer, you will need to restart your browser
after installing Flash.
Adobe and Flash are registered trademarks of Adobe Systems incorporated.
All rights reserved.
